Latest Industry Insights

A recent study has shown the clinical value of proactive, sequencing-based screening in apparently healthy newborns for medically actionable conditions. How might these findings impact the current NBS landscape and what does it mean to the healthcare system on the global level?

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

Scientists around the world are increasingly aware of the environmental footprint of their laboratories, and many are adjusting the way they work day-to-day to offset this impact. In this Industry Insights interview, Agilent's Dr. Michael Frank discusses the safety and efficiency considerations that are fundamentally linked to sustainability and considers why more labs aren’t utilizing consulting services to help them achieve their sustainability goals.

How can the industry as a whole address sustainability issues? What are the key needs and goals of pharma and biopharma laboratories when it comes to sustainability?

Rob Thomas shares some insights about what we can expect from the fourth edition of his book, "Practical Guide to ICP-MS and Other AS Techniques: A Tutorial for Beginners".

Robert Balog describes innovations in microarray testing technology that are contributing to faster turnaround times, automated interpretation and improved coverage.

BetterLife Pharma’s lead candidate is a non-hallucinogenic derivative of LSD that mimics the projected therapeutic properties of LSD. To learn more, we spoke with BetterLife Pharma’s chief operating officer, Dr. Hooshmand Sheshbaradaran, and head of preclinical research, Dr. Abdi Ghaffari.

This article discusses how the culture of canine-derived organoid lines can be used to make meaningful observations in the emerging field of comparative oncology, prompting the next revolution in animal and human cancer studies.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

Dr. Andreas Boehmler explores how the arrival of new flow cytometry platforms finally puts powerful automation within reach for many labs, allowing operators to enumerate stem cells more quickly and accurately for transplant.